Clinical Trials Results - National Cancer Institute

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -7 of 7 Show results per page	View Search Criteria \| Help With Results

Last Modified: 7/14/2005 First Published: 11/24/2002


1.		Phase I/II Study of SGN-00101 in HIV-Positive Patients With High-Grade Anal Squamous Intraepithelial Neoplasia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Prevention				Completed				18 and over				NCI				AMC-035 NCT00052897

Last Modified: 9/3/2008 First Published: 1/26/2003


2.		Phase II Randomized Study of SGN-00101 in Patients With Grade III Cervical Intraepithelial Neoplasia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Prevention				Completed				17 and over				NCI				GOG-0197 NCT00054041

Last Modified: 9/3/2008 First Published: 4/23/2003


3.		Phase II Randomized Study of SGN-00101 in Patients With Grade II or III Cervical Intraepithelial Neoplasia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				BWH-000-P-CONS01 NCI-3074, NCT00060099, 3074

Last Modified: 9/3/2008 First Published: 12/23/2003


4.		Phase II Study of SGN-00101 Immunotherapy in Patients With Grade III Cervical Intraepithelial Neoplasia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Prevention				Completed				18 and over				NCI				AECM-0309225 NCI-5850, NCT00075569, 5850


5.		A Trial Study of SGN-00101 in Treating Pediatric Patients With Recurrent Respiratory Papillomatosis

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Prevention, Treatment				Completed				2 to 18				Pharmaceutical / Industry				Stressgen SGN-00101-0005 SGN-00101-0005, NCT00038714

Last Modified: 4/12/2007 First Published: 8/24/2004


6.		Phase II Randomized Study of SGN-00101 Vaccine in Human Papillomavirus-16-Positive Patients With Atypical Squamous Cells of Undetermined Significance or Low-Grade Squamous Intraepithelial Lesions of the Cervix

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Prevention				Closed				18 to 50				NCI				UCIRVINE-02-55 UCIRVINE-2002-2758, NCT00091130


7.		Safety Study to Test the Safety of HspE7 and Poly-ICLC Given in Patients With Cervical Intraepithelial Neoplasia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Prevention				Closed				18 and over				Pharmaceutical / Industry				HspE7-00101-0601 NCT00493545

Select All on One Page